In SERENA-6, switching from aromatase inhibitor (AI) to camizestrant with continuation of CDK4/6 inhibitor (CDK4/6i) guided by emergence of ESR1 mutations (ESR1-mut) during first-line AI-CDK4/6i in patients with hormone receptor (HR)-positive advanced breast cancer (ABC) resulted in statistically significant and clinically meaningful improvement in progression-free survival compared with AI-CDK4/6i and reduction in the risk of deterioration in global health status…
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy☆
Annals of Oncology | | E.L. Mayer, F.-C. Bidard, Y.H. Park, W. Janni, C. Ma, M. Cristofanilli, H. Iwata, G. Bianchini, K. Kalinsky, S. Chia, A. Brufsky, P.A. Fasching, Z. Nowecki, S.-C. Chen, J. Pascual, L. Moreau, M. Ruiz-Borrego, A. Shai, N. Karadurmus, J.H. Sohn, Y. Zhu, I. Leddin, M.S. Miralles, C.H. Bartlett, N. Turner
Topics: breast-cancer, blood-cancer, clinical-trials